Mutations in the cancer-related genes BRCA1/2 occur frequently in patients with breast, ovarian, prostate and pancreatic cancer. ACTBRCA™ detects those mutations, and the test results help you to find an effective targeted therapy.
Analyzes the genes BRCA1/2 to provide a better treatment strategy. BRCA1/2 mutations increase the risk of developing breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. ACTBRCA™ can help these cancer patients to identify mutations in BRCA1/2, and help to provide treatment strategies. ACTBRCA™ uses NGS to detect multiple genetic mutation types in BRCA1/2
ACTBRCA™ is most suitable for patients who are
￭ Breast Cancer Patients
￭ Ovarian Cancer Patients
￭ Prostate Cancer Patients
￭ Pancreatic Cancer Patients
Typical tissue samples include FFPE (formalin-fixed and paraffin-embedded) tissue, and blood.
14 calendar days after samples are received